MESENCHYMAL STROMAL CELLS

Mesenchymal Stromal Cells (MSC) are a population of multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue).  These characteristics give MSC’s the potential for use as living medicines, which may also exploit their capabilities in anti-inflammatory, immunomodulatory, and cell signalling activity.

The MedXCell Group utilizes MSC’s obtained from the adipose tissue of qualified donors and expanded according to the company’s proprietary methods.  One donor may provide sufficient cells to prepare thousands of patient doses.  The company is pioneering the use of these allogeneic doses to treat osteoarthritis of the knee, a debilitating degenerative condition for which there is no effective long-term treatment other than prosthetic knee replacement.

The MedXCell Group believes that this treatment, currently in late-stage clinical studies, will provide a cost-effective and safe treatment for the millions of patients who experience the life-changing burden of osteoarthritis.

MSC therapy also has potential in many other indications involving mechanical tissue degeneration and chronic pain.

ADIPOSE TISSUE SOURCE (DONOR)
ADIPOSE TISSUE SOURCE (DONOR)
STEP 1: SEPARATION OF STROMAL VASCULAR FRACTION
(24 HOURS)
SVF
SVF
STEP 2: FIRST SELECTION AND EXPANSION
(8 DAYS)
INTERMEDIATE DRUG PRODUCT (INVENTORY)
INTERMEDIATE DRUG PRODUCT (INVENTORY)
STEP 3: SECOND SELECTION AND EXPANSION
(6 DAYS)
FINAL DRUG PRODUCT
FINAL DRUG PRODUCT
STEP 4: CRYOPRESERVATION & SHIPMENT
STEP 5: THAWING & INJECTION